{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:35:37Z","timestamp":1767706537584},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> The combination of interferon alfa-2a (IFN alpha) and high-dose interleukin-2 (IL-2) is active in metastatic melanoma. The addition of cisplatin (CDDP) has resulted in response rates greater than 50%. This study was performed to determine whether the addition of CDDP to a cytokine treatment regimen with IFN alpha and high-dose IL-2 influences survival of patients with metastatic melanoma. <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> Patients with advanced metastatic melanoma were randomly assigned to receive treatment with IFN alpha 10 x 10(6) U\/m2 subcutaneously on days 1 through 5 and a high-dose intravenous decrescendo regimen of IL-2 on days 3 through 8 (18 mIU\/ m2\/6 hours, 18 mIU\/m2\/12 hours, 18 mIU\/m2\/24 hours, and 4.5 mIU\/m2\/24 hours x 3) without (arm A) or with (arm B) CDDP 100 mg\/m2 on day 1. Treatment cycles were repeated every 28 days to a maximum of four cycles. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> One hundred thirty-eight patients with advanced metastatic melanoma, of whom 87% had visceral metastases, were accrued for the trial. Both regimens were feasible in a multicenter setting. The objective response rate was 18% without and 33% with CDDP (P = .04). The progression-free survival was 53 days without and 92 days with CDDP (P = .02, Wilcoxon; P = .09, log-rank). There was no statistically significant difference in survival between treatment arms, with a median overall survival duration for all patients of 9 months. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> The addition of CDDP to cytokine treatment with IFN alpha and IL-2 does not influence survival of patients with advanced metastatic melanoma, despite a significant increase in response rate and progression-free survival. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.1997.15.7.2579","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T09:41:10Z","timestamp":1487929270000},"page":"2579-2588","source":"Crossref","is-referenced-by-count":159,"title":["Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group."],"prefix":"10.1200","volume":"15","author":[{"given":"U","family":"Keilholz","sequence":"first","affiliation":[]},{"given":"S H","family":"Goey","sequence":"additional","affiliation":[]},{"given":"C J","family":"Punt","sequence":"additional","affiliation":[]},{"given":"T M","family":"Proebstle","sequence":"additional","affiliation":[]},{"given":"R","family":"Salzmann","sequence":"additional","affiliation":[]},{"given":"C","family":"Scheibenbogen","sequence":"additional","affiliation":[]},{"given":"D","family":"Schadendorf","sequence":"additional","affiliation":[]},{"given":"D","family":"Li\u00e9nard","sequence":"additional","affiliation":[]},{"given":"A","family":"Enk","sequence":"additional","affiliation":[]},{"given":"R","family":"Dummer","sequence":"additional","affiliation":[]},{"given":"B","family":"Hantich","sequence":"additional","affiliation":[]},{"given":"A M","family":"Geueke","sequence":"additional","affiliation":[]},{"given":"A M","family":"Eggermont","sequence":"additional","affiliation":[]}],"member":"233","container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1997.15.7.2579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:04:21Z","timestamp":1653516261000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1997.15.7.2579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["10.1200\/JCO.1997.15.7.2579"],"URL":"https:\/\/doi.org\/10.1200\/jco.1997.15.7.2579","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}